Featured Research

from universities, journals, and other organizations

Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified

Date:
January 13, 2008
Source:
University of Vermont
Summary:
Preliminary data from two Women's Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism (VTE) with postmenopausal hormone therapy is now available. VTE refers to a blood clot that forms in the veins, usually in the legs. These clots can become fatal if they travel through the veins to the lung. According to the American Heart Association, more than 200,000 cases of VTE occur each year and 30 percent of these people die within three days. It is known that postmenopausal hormone treatments can double the risk of developing VTE, and in recent years hormone prescriptions have declined, partly as a result of this.

University of Vermont cardiovascular physician-scientists Mary Cushman, M.D., and Matthew Watkins, M.D., are conducting cutting-edge research on the number-one killer of men and women in the United States -- cardiovascular disease.

Hormones and blood clot risk

In early December 2007, Cushman presented preliminary data from two Women’s Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism (VTE) with postmenopausal hormone therapy. VTE refers to a blood clot that forms in the veins, usually in the legs. These clots can become fatal if they travel through the veins to the lung. According to the American Heart Association, more than 200,000 cases of VTE occur each year and 30 percent of these people die within three days. It is known that postmenopausal hormone treatments can double the risk of developing VTE, and in recent years hormone prescriptions have declined, partly as a result of this.

“If these findings are confirmed, measurement of some of these factors might assist women with decision-making about whether or not to take estrogen or estrogen plus progestin for treatment of postmenopausal symptoms," said Cushman. "This becomes very important since hormones remain a very effective treatment for menopausal symptoms."

Women with angina better candidates for angiogenic therapy

A reported 8.9 million people in the United States, including 4.6 million women, live with chronic angina, the debilitating chest pain, squeezing or pressure experienced by people with coronary heart disease. However, women with heart disease have been largely underrepresented in cardiovascular clinical trials. A recent study article co-authored by Matthew Watkins, M.D., professor of medicine at the University of Vermont College of Medicine, indicates that an experimental treatment designed to promote blood vessel growth and improve cardiovascular blood flow in patients with angina may have a positive treatment effect in women as opposed to men.

The AGENT (Angiogenic Gene Therapy) studies (1 through 4) have to date involved 663 patients at more than one hundred U.S., European and other international medical centers. The experimental therapy under examination in the AGENT trials is Generx™ (alferminogene tadenovec, Ad5FGF-4), a gene product in a new class of cardiovascular biologics that when administered by intracoronary injection, promotes angiogenesis – the process of blood vessel growth in the heart. For their September 11, 2006 Journal of American College of Cardiology article, Watkins and his colleagues analyzed pooled original data from the AGENT -3 and -4 trials to determine treatment effects in two subgroups, gender and older patients with severe angina.

The study used exercise tolerance testing time to track any changes from baseline at 4 weeks, 12 weeks and 6 months among three groups – placebo, low-dose Ad5FGF-4 and high-dose Ad5FGF-4. At 12 weeks, there was significant improvement in women at both doses, but not in men.

Based on these findings, a Phase 3 clinical trial titled AWARE (Angiogenesis in Women with Angina pectoris who are not candidates for Revascularization) was launched in August 2007. UVM is one of more than two dozen centers in the country currently participating in this trial, which aims to enroll approximately 300 women with chronic angina who are not candidates for conventional bypass surgery or angioplasty in order to more closely examine the effects of angiogenic therapy on this population of patients.


Story Source:

The above story is based on materials provided by University of Vermont. Note: Materials may be edited for content and length.


Cite This Page:

University of Vermont. "Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified." ScienceDaily. ScienceDaily, 13 January 2008. <www.sciencedaily.com/releases/2008/01/080111200419.htm>.
University of Vermont. (2008, January 13). Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/01/080111200419.htm
University of Vermont. "Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified." ScienceDaily. www.sciencedaily.com/releases/2008/01/080111200419.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins